Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors
Phase of Trial: Phase II
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adrenocortical carcinoma; Paraganglioma; Penile cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Testicular cancer; Thymoma; Thyroid cancer
- Focus Therapeutic Use
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 15 Aug 2016 Status changed from not yet recruiting to recruiting.
- 15 Aug 2016 Planned primary completion date changed from 1 Sep 2019 to 1 Aug 2019.